E Fund CSI WD Biotechnology Index Fund(LOF)-A

161122

516060

520970

<p>The CSI Innovative Drugs Industry Index surged 11% over the past week. Brokerages believe the innovative drug sector is in a stage of "earnings realization, valuation repair, and conference catalysis." Multiple biopharmaceutical companies have achieved historic turnarounds, with fundamentals improving. In the first quarter of this year, the total amount of China's innovative drug out-licensing reached nearly $57 billion, already exceeding the full-year level of 2024. The upcoming AACR and ASCO annual meetings, with intensive clinical data disclosures, are expected to provide catalysts</p>

Wallstreetcn

ICBCCS CSI Brand Name Drug Industry ETF

Harvest CSI Hong Kong Connect Innovative Drugs ETF

E Fund CSI Innovative Drugs ETF

J.P.Morgan Asset Management CSI Brand Name Drug Industry ETF

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Guotai SSE STAR Brand Name Drug ETF

E Fund Hang Seng SCHK Innovative Drug ETF

CCB Principal CSI Innovative Drugs Industry ETF

Wanjia CSI Hong Kong Connect Innovative Drugs ETF

Invesco Great Wall CSI Hong Kong Connect Innovative Drug ETF

Eastmoney Fund CSI SH-HK-SZ Brand Name Drug Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Yinhua CSI Innovative Drugs Industry ETF

Innovative Drugs Break Out Again After Six Months, Leading Companies Enter Intensive Harvest Period; Has the Profit Inflection Point Arrived?

E Fund CSI WD Biotechnology Index Fund(LOF)-A(161122.SZ)

Innovative Drugs Break Out Again After Six Months, Leading Companies Enter Intensive Harvest Period; Has the Profit Inflection Point Arrived?